Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;25(9):749-757.
doi: 10.1634/theoncologist.2019-0744. Epub 2020 Jul 7.

Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer

Debora de Melo Gagliato  1 , Xiudong Lei  2 , Sharon H Giordano  2   3 , Vicente Valero  3 , Carlos H Barcenas  3 , Gabriel N Hortobagyi  3 , Mariana Chavez-MacGregor  2   3
Affiliations

Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer

Debora de Melo Gagliato et al. Oncologist. 2020 Sep.

Abstract

Background: Delays in the initiation of therapy among patients with early stage breast cancer (BC) can negatively affect outcomes. Patients treated with neoadjuvant systemic chemotherapy (NSC) usually display tumors with high-risk features. Considering these high-risk characteristics and the evidence supporting adverse outcomes associated with delays in adjuvant chemotherapy initiation, we sought to determine whether a delay in NSC initiation is associated with overall survival (OS).

Methods: We identified patients diagnosed between January 1995 and December 2015 with invasive primary BC (stage I-III) who received NSC at MD Anderson Cancer Center. Patients were categorized according to their time from BC diagnosis to NSC (in days) into three subgroups: 0-30, 31-60, and ≥61 days. Primary endpoint was OS. Descriptive statistics and Cox's proportional hazard models were used.

Results: A total of 5,137 patients were included. Median follow-up was 6.5 years. The 5-year OS estimates according to time to NSC were 87%, 85%, and 83% in patients who received NSC within 0-30, 31-60, and ≥61 days after diagnosis, respectively (p = .006). In multivariable analysis, compared with time to NSC of 0-30 days, delayed NSC ≥61 days was associated with an increased risk of death (31-60 days: hazard ratio [HR] = 1.05 [95% confidence interval (CI) 0.92-1.19]; ≥61 days, HR = 1.28 [95% CI 1.06-1.54]). In stratified analyses, the association between delay in NSC initiation and increased risk of death was statistically significant for patients with stage I and II BC (31-60 days: HR = 1.22 [95% CI 1.02-1.47]; ≥61 days, HR = 1.41 [95% CI 1.07-1.86]) and among patients with HER2-positive tumors ( ≥61 days, HR = 1.86 [95% CI 1.21-2.86]).

Conclusion: A delay in NSC initiation of more than 61 days after BC diagnosis was associated with an increased risk of death. Early initiation of NSC should be a priority; multidisciplinary teams must focus on coordination of care and patient-centered, timely treatment planning and delivery.

Implications for practice: The results of this study showed that a delay in neoadjuvant systemic chemotherapy initiation of more than 61 days after breast cancer diagnosis is associated with an increased risk of death; therefore, efforts must focus on early initiation of therapy, which should be a priority. Multidisciplinary teams must enhance coordination of care and patient-centered, timely treatment planning and delivery.

Keywords: Locoregional breast cancer; Neoadjuvant chemotherapy; Time to systemic therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Figures

Figure 1
Figure 1
Time to neoadjuvant systemic chemotherapy according to year of diagnosis.
Figure 2
Figure 2
Kaplan‐Meier estimates of overall survival according to time to neoadjuvant systemic chemotherapy. Abbreviation: NST, neoadjuvant systemic therapy.
See this image and copyright information in PMC

References

    1. Guo F, Kuo YF, Shih YCT et al. Trends in breast cancer mortality by stage at diagnosis among young women in the United States. Cancer 2018;124:3500–3509. - PMC - PubMed
    1. Welch HG, Prorok PC, O'Malley AJ et al. Breast‐cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med 2016;375:1438–1447. - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group ; Peto R, Davies C, Godwin J et al. Comparisons between different polychemotherapy regimens for early breast cancer: Meta‐analyses of long‐term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432–444. - PMC - PubMed
    1. Bleicher RJ, Ruth K, Sigurdson ER et al. Time to surgery and breast cancer survival in the United States. JAMA Oncol 2016;2:330–339. - PMC - PubMed
    1. Gagliato Dde M, Gonzalez‐Angulo AM, Lei X et al. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 2014;32:735–744. - PMC - PubMed

Publication types